Mortality Vital Statistics
Merck’s Winrevair Slashes Morbidity and Mortality Risk in Pulmonary Arterial Hypertension
Winrevair, pulmonary arterial hypertension (PAH), Phase III ZENITH trial, morbidity, mortality, Merck
ACC25: Merck & Co.’s Winrevair reduces mortality in most severe PAH patients
Pulmonary arterial hypertension, Winrevair, Severe (severity modifier), Mortality Vital Statistics
Merck’s Winrevair Demonstrates Significant Mortality Benefit in Pulmonary Arterial Hypertension Patients
Winrevair, Pulmonary Arterial Hypertension (PAH), Mortality Benefit, Sotatercept, Merck & Co.
Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study
Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality
Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease
** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment
Semaglutide Significantly Improves Cardiovascular Health and Reduces Mortality Risk in Kidney Disease Patients, Novo Reports
Semaglutide, Novo, cardiovascular health, kidney disease, mortality risk, clinical trial